|1.||Takaki, Machiko: 1 article (01/2015)|
|2.||Kawamura, Tatsuyoshi: 1 article (01/2015)|
|3.||Shibagaki, Naotaka: 1 article (01/2015)|
|4.||Inozume, Takashi: 1 article (01/2015)|
|5.||Shimada, Shinji: 1 article (01/2015)|
|6.||Harada, Kazutoshi: 1 article (01/2015)|
|7.||Matsuzawa, Takamitsu: 1 article (01/2015)|
|8.||Chang, Hong: 1 article (01/2013)|
|9.||Dang, Harry: 1 article (01/2013)|
|10.||Jiang, Allan: 1 article (01/2013)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/01/1997 - "Since the CD7 antigen is also expressed on AML cells, TXU-PAP could also be useful for the treatment of CD7 positive acute myeloid leukemia (AML) patients."
01/01/2013 - "We investigated the genetic mutations NPM1, FLT3-ITD, and FLT3-TKD and expression of the membrane antigens CD7, CD15, CD34, and CD56 in 144 elderly patients with de novo normal karyotype acute myeloid leukemia to retrospectively analyze the prognostic and clinical relevance of these parameters. "
09/01/1998 - "CD7 antigen has until recently been considered to be a T-cell marker but has been found to be expressed by leukemic cells from some acute myeloid leukemia (CD7+ AML) and the normal putative counterparts of blasts from CD7+ AML can be found in human fetal livers. "
03/01/1995 - "The clinical significance of the expression of CD7 antigen on the blasts of 207 consecutive patients with de novo acute myeloid leukemia (AML) was evaluated. "
03/01/1994 - "Six patients with acute myeloid leukemia (AML) expressing CD7 antigen (CD7+ AML) were studied. "
12/01/2009 - "Frequent CD7 antigen loss in aggressive natural killer-cell leukemia: a useful diagnostic marker."
07/01/2003 - "In addition, immunophenotypic analysis revealed the coexpression of the CD33 and CD7 antigens on common ALL blasts, in accordance with other reported cases that displayed a predominant biphenotypic leukemia profile. "
07/01/1995 - "Fourteen cases of lymphoid and myeloid acute leukemia (AL) were studied for expression on blast cells of CD7 antigen, a cell surface marker found early during T lineage differentiation. "
01/01/1990 - "In a study of 100 consecutive de novo ANLL patients diagnosed by FAB criteria, T-cell antigen CD7 was identified on the leukemic blasts of 13 patients, ten of whom had M1 subtype of leukemia, myeloblastic leukemia without maturation. "
10/01/1997 - "In clonogenic assays, TXU-PAP elicited selective and potent cytotoxicity against CD7 antigen positive human leukemia cells and killed primary clonogenic leukemic cells from T-lineage acute lymphoblastic leukemia (ALL) patients. "
02/01/1989 - "None of the ATL cases had the CD7 antigen in this study using WT 1 as a CD7 antibody, which is in contrast with the non-ATL lymphomas in which 13 of 25 cases expressed CD7. "
01/01/1989 - "The T-lymphoblastic lymphomas and leukemias we analysed phenotypically shared the constant features of CD7 antigen expression, whereas other T-cell features showed a clear variability."
05/01/2004 - "The PEL tumor cells harbored a homogenous and isolated trisomy 12 in case 1 and an aberrant expression of the T-cell lineage antigen CD7 in case 2. Both patients were lymphopenic at the time of PEL diagnosis and rapidly died with progressive lymphoma. "
01/01/2010 - "We also found loss of CD3 and CD7 antigens in tumor stage what might be use as adiagnosis tool for this disease. "
07/01/2003 - "CD5 and CD7 antigens were expressed in 12.3% and 19.5% of cases of nonhematopoietic tumors, respectively. "
12/01/2001 - "As a result of the frequent loss of CD7 antigen, only 25+/95 (26%) of peripheral T cell neoplasms were found to be positive for CBC.37. "
12/01/1989 - "The tumor cells expressed, CD2, CD3, CD4, CD5 and CD7 antigens, which corresponded to the phenotype of helper-inducer T-lymphocytes. "
04/01/1990 - "In two cases the tumor cells acquired the CD7 antigen or lost the CD2 antigen with progression of the disease. "
|5.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
08/01/2011 - "Cytoplasmic CD3 and CD7 antigens were positive in all T-ALL cases. "
09/01/2000 - "cCD3 and CD7 antigens were identified in 71% and 100% of T-ALL, respectively. "
09/01/1987 - "Among the patients with poor prognostic factors, those with pre-T ALL as well as those with T-ALL, which were positive for CD7 antigen, were found to have significantly short disease-free survival times (P less than 0.03). "
02/01/1994 - "The CD21 antigen was expressed by one of the eight cases of neoplastic lymphoid cells expressing the CD7 antigen as a sole pan-T antigen, by three of the 20 cases of pro- or early thymic stage (CD7+ CD5+ CD2-, CD7+ CD5- CD2+, or CD7+ CD5+ CD2+, and ten of 11 cases of thymic stage (CD3+/- CD4+ CD8+), but not by one case of late thymic stage (CD3+ CD4+ CD8-) T-ALL/LBL cells. "
|2.||HLA-DR Antigens (HLA-DR)
|3.||Tumor Viral Antigens (Large T Antigen)
|6.||Complement 3d Receptors (Complement Receptor 2)
|7.||Interleukin-2 Receptors (IL 2 Receptor)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)